Keyword: Cydan

CEOs weigh in on increasingly large biotech IPOs and an increase in companies going public at earlier stages.

Drug accelerator Cydan is hiring on Yongchang Qiu, Ph.D., as vice president of preclinical development and Ryan Tyler, Ph.D., as senior director of preclinical research.

Tiburio Therapeutics starts life with $31 million in series A funding and a pair of clinical-stage compounds licensed from Ipsen.

Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.

The biotech builders at Cydan Development have launched their second rare-disease venture, gathering a $31 million cash cache from a group of A-list backers that includes Pfizer and New Enterprise Associates.